iion talk - ayoung

7/29/2019 Iion Talk - AYoung

1/16

OPENING DOORS

FOR NEW IDEAS

A Tested Form u la

fo r Tech Startups


2/16

Alan J. Young, PhD.

Academic:

Professor and Research Leader, Department ofVeterinary and Biomedical Sciences

Project Leader, Center for Emerging Zoonoses andAnimal Disease

Business:

Technology Lead, Life Sciences Portfolio,Innovation Partners

Chief Scientific Officer and Founder, MedgeneLabs, LLC.


3/16

Alan J. Young, PhD.

2001 Assistant Professor, South Dakota State University Research focus on Sheep Immunology, Prion Diseases

2004 DOD Prion Research Program releases prion SmallBusiness Innovation Research RFA

From 2004-2010, received approx $2M in SBIR Phase I and PhaseII Research Funding in partnership with Rural Technologies Inc,and Chronix Biomedical, Brookings, SD.

2010 All IP and equipment acquired by Medgene Labs, anew startup company with initial investment by InnovationPartners.

2012 Assumed role as Technology Lead for Life SciencesPortfolio Companies


4/16

Innovation Partners Overview

Early-Stage Venture Capital Firm Focus on Research Commercialization

De-Risking Market-Aligned Technologies

Between Basic Research at Universities

and Corporate Product Development Technology Transfer, Seed Capital, and

World-Class Business Development

Portfolio Company Investment Strategy

Agriculture Technologies

Life Sciences

Engineered Technologies


5/16

Overcoming the Valley of Death


6/16

De-Risking Strategy

Market

Team

TechnologyIntellectual

Property

BusinessModel


7/16

Funding Strategies

Primary Investment and businessmanagement is provided by InnovationPartners, leveraged through:

State and Federal Grant Opportunities SBIR/STTR Program NIH, NSF, USDA

State Workforce Development Programs

Product Development and Contractual

Relationships with Federal and Private Partners Where appropriate, low-interest or forgivable

loans.


8/16

Medgene Labs uses a combination of advancedand proven in vitro evaluation systems and in vivotrials to develop vaccines and antibody-based

diagnostics and therapeutics to meet the needsof animal and human health.

Product development is a combination of in-house and end-licensed technology from

academia. Our product development focus is on emerging

zoonoses and vector-borne diseases.


9/16

Enabling Technologies

MAX400TM Detection

Rapid X SystemTM Screening

Adjuvant Systems InAcTTM - Innovation in Biotechnology Award

Peptide Hydrogel

Delivery Systems NaturprozTM

NaturmiczTM


10/16

Target Identification

-CEEZAD, USDA

-Universities

Production/Delivery

-Insect Cell Synthesis

- TranzDerm

-InAcT

Adjuvant

-InAcT, Peptide Hydrogel

-Seppic

RapidXScreening of Formulations

In vivo Challenge Studies

Rift Valley Fever

Influenza

Tick-Borne Diseases

PRRSV Epitoozotic Hemorrhagic

Disease


11/16

Interdisciplinary Approach to Innovation

Formulation

/ Delivery

Systems

Thin Films

Renewable Oil /

Soil Amendment

Renewable Oil /

Protein Enhancement

Microbial-Based

Chemical Production

Animal and Human Health

Diagnostics / Therapeutics

Protein Enhancement /

Aquaculture Technologies


12/16

Current Scorecard

Investment Capital: $6.0MDeals Reviewed: 800+

Start-Up Companies: 10

Patent Applications: 30+

Team Members: 30+

Strategic Partners: 30+

Grant Proposals: 30+

Grant Awards: 10 $2.5MOther Commitments: $3.5M

Entrepreneurial Leverage


13/16

Importance of Partnerships

Open Innovation Co-Development

Entrepreneurial Exchange

Scientific Exchange

Co-Investment

Innovation Fund I Exit Opportunities

License

Acquisition

Innovation Fund II Capital

Opportunities


14/16

Current Scorecard

Investment Capital: $6.0MDeals Reviewed: 800+

Start-Up Companies: 10

Patent Applications: 30+

Team Members: 30+

Strategic Partners: 30+

Grant Proposals: 30+

Grant Awards: 10 $2.5MOther Commitments: $3.5M

Entrepreneurial Leverage

S hb d l H 400 l d


15/16

Southbound lanes on Hwy. 400 closed

due to tractor fire Sept 20, 2013


16/16

SD Traffic to Holiday Country..

iion talk - ayoung

Documents